2-[(6-dimethylaminomethyl-pyridin-2-yl)methylthio]ethylamine | 78442-44-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-[(6-dimethylaminomethyl-pyridin-2-yl)methylthio]ethylamine
• 英文别名: 2-<<<6-<(dimethylamino)methyl>-2-pyridyl>methyl>thio>ethylamine；2-[(2-aminoethyl)thiomethyl]-6-dimethylaminomethyl pyridine；2-[(6-dimethylaminomethyl-2-pyridyl)methylthio]ethylamine；2-[({6-[(dimethylamino)methyl]-2-pyridyl}methyl)thio]ethylamine；2-[[6-[(dimethylamino)methyl]pyridin-2-yl]methylsulfanyl]ethanamine
• CAS: 78442-44-1
• 化学式: C₁₁H₁₉N₃S
• 分子量: 225.358
• InChiKey: UUAJSQSNRAMSDP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  67.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-[(6-dimethylaminomethyl-pyridin-2-yl)methylthio]ethylamine 、 3,4-二甲氧基-1,2,5-噻二唑 1,1-二氧化物 生成 3-Amino-4-{2-[(6-dimethylaminomethyl-pyridin-2-yl)methylthio]ethylamino}-1,2,5-thiadiazole 1,1-dioxide
  参考文献：
  名称：

  Chemical compounds

  摘要：

  组胺H.sub.2-拮抗剂的化学结构为##STR1##，其中p为1或2；R.sup.1为羟基、氨基、取代氨基或通过其氮原子连接的5至9成员完全饱和的含氮杂环环；m为0至2的整数；n为2至4的整数；Z为硫、氧或亚甲基；A为可选择取代的苯基、咪唑基、噻唑基、异噻唑基、噁唑基、异噁唑基、三唑基、噻二唑基、噁二唑基、呋喃基、噻吩基或吡啶基环；以及其非毒性的药学可接受的盐、水合物、溶剂合物或N-氧化物是新型抗溃疡药物。揭示了其中间体和制备方法。

  公开号：

  US04394508A1
• 作为产物：
  描述：

  2,6-二氯甲基吡啶 在 sodium methylate 、 甲胺 作用下， 以 甲醇 为溶剂， 反应 79.0h， 生成 2-[(6-dimethylaminomethyl-pyridin-2-yl)methylthio]ethylamine
  参考文献：
  名称：

  在一系列新型组胺H2受体拮抗剂中分子内相互作用的结构活性，理论和X射线研究。

  摘要：

  组胺H 2受体拮抗剂的呋喃环3-氨基-4-[[2-[[[5-[（[二甲基氨基）甲基] -2-呋喃基]-甲基]硫代]乙基]氨基] -1,2,5用噻吩，吡啶，苯和吡咯代替1-噻二唑一氧化物（1a）。这些类似物的相对受体亲和力通过体外和体内技术估算。建立了通过1a的单晶X射线分析观察到的堆叠相互作用的理论模型，并评估了进入这种相互作用的能力。对1a的吡啶类似物的X射线分析表明没有分子内堆积相互作用。根据观察到的受体亲和力对理论研究进行了评估，并评估了1a固态几何形状与受体结合几何形状的相关性。

  DOI：

  10.1021/jm00374a019

文献信息

• Thiadiazole histamine H.sub.2 -antagonists
  申请人：Bristol-Myers Company

  公开号：US04471122A1

  公开（公告）日：1984-09-11

  Histamine H.sub.2 -antagonists of the formula ##STR1## wherein p is 1 or 2; R.sup.1 is hydroxy, amino, substituted amino or a 5- to 9-membered fully saturated nitrogen-containing heterocyclic ring attached via its nitrogen atom; m is an integer of from 0 to 2; n is an integer of from 2 to 4; Z is sulfur, oxygen or methylene; and A is an optionally substituted phenyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, thiadiazolyl, oxadiazolyl, furyl, thienyl or pyridyl ring; and nontoxic pharmaceutically acceptable salts, hydrates, solvates or N-oxides thereof are novel anti-ulcer agents. Intermediates and processes for their preparation are disclosed.

  组织名称为##STR1##的组织胺H.sub.2-拮抗剂，其中p为1或2；R.sup.1为羟基、氨基、取代氨基或通过其氮原子连接的含氮5-至9-成员完全饱和的杂环环；m为0到2的整数；n为2到4的整数；Z为硫、氧或亚甲基；A为可选择取代的苯基、咪唑基、噻唑基、异噻唑基、噁唑基、异噁唑基、三唑基、噻二唑基、噁二唑基、呋喃基、噻吩基或吡啶基环；以及其新型抗溃疡剂的无毒药用盐、水合物、溶剂合物或N-氧化物。披露了其制备的中间体和方法。
• Chemical compounds
  申请人：Bristol-Myers Company

  公开号：US04394508A1

  公开（公告）日：1983-07-19

  Histamine H.sub.2 -antagonists of the formula ##STR1## wherein p is 1 or 2; R.sup.1 is hydroxy, amino, substituted amino or a 5- to 9-membered fully saturated nitrogen-containing heterocyclic ring attached via its nitrogen atom; m is an integer of from 0 to 2; n is an integer of from 2 to 4; Z is sulfur, oxygen or methylene; and A is an optionally substituted phenyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, thiadiazolyl, oxadiazolyl, furyl, thienyl or pyridyl ring; and nontoxic pharmaceutically acceptable salts, hydrates, solvates or N-oxides thereof are novel anti-ulcer agents. Intermediates and processes for their preparation are disclosed.

  组胺H.sub.2-拮抗剂的化学结构为##STR1##，其中p为1或2；R.sup.1为羟基、氨基、取代氨基或通过其氮原子连接的5至9成员完全饱和的含氮杂环环；m为0至2的整数；n为2至4的整数；Z为硫、氧或亚甲基；A为可选择取代的苯基、咪唑基、噻唑基、异噻唑基、噁唑基、异噁唑基、三唑基、噻二唑基、噁二唑基、呋喃基、噻吩基或吡啶基环；以及其非毒性的药学可接受的盐、水合物、溶剂合物或N-氧化物是新型抗溃疡药物。揭示了其中间体和制备方法。
• Aminoalkyl pyridine derivatives
  申请人：Merck & Co., Inc.

  公开号：US04490533A1

  公开（公告）日：1984-12-25

  There are disclosed novel compounds described as aminoalkyl pyridine derivatives in which the aminoalkyl pyridine is connected to a guanidine moiety or a functional equivalent thereof, either directly or through a linear connecting group. Processes for the preparation of such compounds are also disclosed. The compounds are useful for the suppression of gastirc acid secretions in mammals and compositions for such uses are also disclosed.

  已披露了描述为氨基烷基吡啶衍生物的新化合物，其中氨基烷基吡啶连接到胍嘧啶基团或其功能等效物中，可以直接连接或通过线性连接基团连接。还披露了制备这种化合物的方法。这些化合物对于抑制哺乳动物的胃酸分泌是有用的，同时也披露了用于此类用途的组合物。
• Substituted 1,2,5-thiadiazole derivatives
  申请人：Bristol-Myers Company

  公开号：US04380639A1

  公开（公告）日：1983-04-19

  Histamine H.sub.2 -antagonists of the formula ##STR1## wherein p is 1 or 2; R.sup.1 is hydroxy, amino, substituted amino or a 5- to 9-membered fully saturated nitrogen-containing heterocyclic ring attached via its nitrogen atom; m is an integer of from 0 to 2; n is an integer of from 2 to 4; Z is sulfur, oxygen or methylene; and A is an optionally substituted phenyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, thiadiazolyl, oxadiazolyl, furyl, thienyl or pyridyl ring; and nontoxic pharmaceutically acceptable salts, hydrates, solvates or N-oxides thereof are novel anti-ulcer agents. Intermediates and processes for their preparation are disclosed.

  该专利涉及一种组成式为##STR1##的组织胺H.sub.2-拮抗剂，其中p为1或2；R.sup.1为羟基，氨基，取代氨基或通过其氮原子连接的5-至9-成员完全饱和的含氮杂环；m为0到2的整数；n为2到4的整数；Z为硫，氧或亚甲基；而A为可选的取代苯基，咪唑基，噻唑基，异噻唑基，噁唑基，异噁唑基，三唑基，噻二唑基，氧杂二唑基，呋喃基，噻吩基或吡啶基；以及其非毒性医药上可接受的盐，水合物，溶剂合物或N-氧化物是新的抗溃疡剂。还公开了其中间体和制备方法。
• 3,4-Disubstituted-1,2,5-thiadiazole-1-oxide compounds
  申请人：Bristol-Myers Company

  公开号：US04374248A1

  公开（公告）日：1983-02-15

  Histamine H.sub.2 -antagonists of the formula ##STR1## wherein p is 1 or 2; R.sup.1 is hydroxy, amino, substituted amino or a 5- to 9-membered fully saturated nitrogen-containing heterocyclic ring attached via its nitrogen atom; m is an integer of from 0 to 2; n is an integer of from 2 to 4; Z is sulfur, oxygen or methylene; and A is an optionally substituted phenyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, thiadiazolyl, oxadiazolyl, furyl, thienyl or pyridyl ring; and nontoxic pharmaceutically acceptable salts, hydrates, solvates or N-oxides thereof are novel anit-ulcer agents. Intermediates and processes for their preparation are disclosed.

  结构式为 ##STR1## 的组胺H.sub.2-拮抗剂，其中p为1或2；R.sup.1为羟基，氨基，取代氨基或通过其氮原子连接的具有5-至9-成员完全饱和的含氮杂环环；m为0至2的整数；n为2至4的整数；Z为硫，氧或亚甲基；A为可选取代的苯基，咪唑基，噻唑基，异噻唑基，噁唑基，异噁唑基，三唑基，噻二唑基，氧杂二唑基，呋喃基，噻吩基或吡啶基环；以及其非毒性药学上可接受的盐，水合物，溶剂合物或N-氧化物是新型抗溃疡剂。公开了它们的中间体和制备方法。